Metropolitan Life Insurance Co NY Increases Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Metropolitan Life Insurance Co NY lifted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 112,266.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,371 shares of the company’s stock after purchasing an additional 3,368 shares during the period. Metropolitan Life Insurance Co NY’s holdings in USANA Health Sciences were worth $345,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp increased its position in shares of USANA Health Sciences by 3.5% during the second quarter. State Street Corp now owns 375,058 shares of the company’s stock worth $38,417,000 after purchasing an additional 12,701 shares in the last quarter. Geode Capital Management LLC increased its position in shares of USANA Health Sciences by 6.6% during the second quarter. Geode Capital Management LLC now owns 217,820 shares of the company’s stock worth $22,311,000 after purchasing an additional 13,511 shares in the last quarter. Northern Trust Corp increased its position in shares of USANA Health Sciences by 1.1% during the second quarter. Northern Trust Corp now owns 150,483 shares of the company’s stock worth $15,414,000 after purchasing an additional 1,573 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of USANA Health Sciences by 5.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 131,600 shares of the company’s stock worth $13,480,000 after purchasing an additional 6,251 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of USANA Health Sciences by 91.3% during the second quarter. JPMorgan Chase & Co. now owns 88,971 shares of the company’s stock worth $9,113,000 after purchasing an additional 42,457 shares in the last quarter. Institutional investors and hedge funds own 54.82% of the company’s stock.

Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $117.00 price target on the stock in a research report on Wednesday, November 17th. Tigress Financial restated a “buy” rating and issued a $122.00 price target on shares of USANA Health Sciences in a research report on Friday, October 8th.

Shares of USNA stock opened at $101.80 on Thursday. The stock has a market capitalization of $1.98 billion, a PE ratio of 15.54 and a beta of 0.84. USANA Health Sciences, Inc. has a 52-week low of $74.20 and a 52-week high of $107.85. The stock’s 50-day moving average price is $96.83 and its 200 day moving average price is $98.78.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 26th. The company reported $1.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.06. USANA Health Sciences had a return on equity of 32.68% and a net margin of 11.05%. The firm had revenue of $274.35 million for the quarter, compared to analysts’ expectations of $268.70 million. During the same quarter in the previous year, the firm posted $1.44 EPS. As a group, equities research analysts predict that USANA Health Sciences, Inc. will post 5.98 earnings per share for the current year.

In other news, Director John Turman Fleming sold 300 shares of the business’s stock in a transaction that occurred on Monday, August 30th. The stock was sold at an average price of $97.26, for a total transaction of $29,178.00. Following the sale, the director now owns 851 shares of the company’s stock, valued at approximately $82,768.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Mulham Mulham sold 569 shares of the business’s stock in a transaction that occurred on Monday, November 15th. The stock was sold at an average price of $102.00, for a total value of $58,038.00. The disclosure for this sale can be found here. Insiders have sold a total of 3,947 shares of company stock worth $393,759 in the last quarter. 0.21% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.